A Review on Neuropharmacology: Mechanisms, Drug Classes, and Clinical Applications
DOI:
https://doi.org/10.22270/ajprd.v14i01.1709Abstract
Background: Neuropharmacology is a vital branch of pharmacology that focuses on the interaction of drugs with the nervous system, particularly the central and peripheral nervous systems. It plays a crucial role in understanding neurotransmission and in the treatment of neurological, psychiatric, and neurodegenerative disorders such as depression, schizophrenia, epilepsy, Parkinson’s disease, and Alzheimer’s disease.
Methods:This review was conducted through a comprehensive analysis of existing experimental and clinical literature on neuropharmacology. Key areas reviewed include the organization of the nervous system, major neurotransmitters, synaptic transmission mechanisms, mechanisms of drug action, classification of neuropharmacological agents, and their clinical applications. Special emphasis was placed on drug–receptor interactions, neurotransmitter modulation, and challenges in central nervous system drug delivery, including blood–brain barrier limitations.
Results: The review highlights that neuropharmacological drugs exert their effects primarily by modulating neurotransmitter release, receptor activation or blockade, reuptake inhibition, and enzyme inhibition. Major drug classes such as antidepressants, antipsychotics, anxiolytics, antiepileptics, analgesics, and antiparkinsonian agents have shown significant clinical benefits. However, adverse effects, drug dependence, tolerance, and limited brain penetration remain major concerns. Emerging strategies such as nanocarriers, receptor-mediated transport, and intranasal delivery show promise in overcoming current therapeutic limitation
Downloads
References
Rang HP, Dale MM, Ritter JM, Flower RJ, Henderson G. Rang and Dale's pharmacology. 9th ed. London: Elsevier; 2020.
Brunton LL, Hilal-Dandan R, Knollmann BC, editors. Goodman & Gilman's the pharmacological basis of therapeutics. 13th ed. New York: McGraw-Hill Education; 2018.
Katzung BG, Vanderah TW. Basic and clinical pharmacology. 15th ed. New York: McGraw-Hill Education; 2021.
Nestler EJ, Hyman SE, Malenka RC. Molecular neuropharmacology: a foundation for clinical neuroscience. 3rd ed. New York: McGraw-Hill Medical; 2015.
Stahl SM. Stahl's essential psychopharmacology: neuroscientific basis and practical applications. 5th ed. Cambridge: Cambridge University Press; 2021.
Chinta SJ, Andersen JK. Dopaminergic neurons. Int J Biochem Cell Biol. 2005;37(5):942–946. doi:10.1016/j.biocel.2004.09.009.
Organization and functions of the nervous system. In: Lange et al. Human Anatomy. Medicine LibreTexts; 2022 Jun 22. Available from: https://med.libretexts.org
Neurotransmission: neurotransmitters. Dana Foundation. 2023 Sep 22. Available from: https://dana.org/resources/neurotransmission-neurotransmitter
Rathi S, Shah S, Raval AM, Patel D, Goswami A. Physicochemical characterization and in-vitro dissolution enhancement of ranolazine using solid dispersion method. J Emerg TechnolInnov Res. 2019; 6(3):866–883.
Magdaleno Roman JY, Chapa González C. Glutamate and excitotoxicity in central nervous system disorders: ionotropic glutamate receptors as a target for neuroprotection. Neuroprotection. 2024; 2(2):137–150. doi:10.1002/nep3.46.
Pourhamzeh M, Moravej FG, Arabi M, Shahriari E, Mehrabi S, Ward R, et al. The roles of serotonin in neuropsychiatric disorders. Cell Mol Neurobiol. 2022; 42(6):1671–1692. doi:10.1007/s10571-021-01106-x.
Sheffler ZM, Reddy V, Pillarisetty LS. Physiology, neurotransmitters. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025.
Advances in neuropharmacology-mechanisms, therapeutic targets, and future perspectives. ScienceHood Publishing; 2025. Available from: https://www.sciencehoodpublishing.org
Sulzer D, Sonders MS, Poulsen NW, Galli A. Mechanisms of neurotransmitter release by amphetamines: a review. Prog Neurobiol. 2005;75(6):406–433. doi:10.1016/j.pneurobio.2005.04.003.
Rossetto O, Pirazzini M, Montecucco C. Botulinum neurotoxins: genetic, structural and mechanistic insights. Nat Rev Microbiol. 2014;12(8):535–549. doi:10.1038/nrmicro3295.
Katzung BG, Trevor AJ. Basic & clinical pharmacology. 13th ed. New York: McGraw-Hill Education; 2014.
Finberg JPM, Rabey JM. Inhibitors of MAO-A and MAO-B in psychiatry and neurology. Front Pharmacol.2016; 7:340. (Verify page details if needed.)
Kapur S, Mamo D. Half a century of antipsychotics and still a central role for dopamine D₂ receptors. Prog NeuropsychopharmacolBiol Psychiatry. 2003;27(7):1081–1090.
Griffin CE 3rd, Kaye AM, Bueno FR, Kaye AD. Benzodiazepine pharmacology and central nervous system–mediated effects. Ochsner J. 2013;13(2):214–223.
Lane CA, Hardy J, Schott JM. Alzheimer’s disease. Eur J Neurol. 2018; 25(1):59–70. doi:10.1111/ene.13439.
Parkinson’s disease. National Institute of Neurological Disorders and Stroke (NINDS). Available from: https://www.ninds.nih.gov
Scholar’s Digest: Journal of Pharmacology. Available from: https://scholarsdigest.org.in
Mian MU, Afzal M, Butt AA, Ijaz M, Khalil K, Abbasi M, et al. Neuropharmacology of neuropathic pain: a systematic review. Cureus. 2024;16(9):e69028. doi:10.7759/cureus.69028.
Feldman EL, et al. Diabetic neuropathy. Nat Rev Dis Primers. 2019;5(1):42. doi:10.1038/s41572-019-0097-9.
Raval AM, Suthar AM, Durani B, Thakar NJ, Zankhwala FM, Kushkiwala AM, Rathod SR. Smart co-processed excipient platforms: a novel strategy for multifunctional optimization of ibuprofen tablet formulations. J Appl Bioanal. 2025;11(15S):103–128.
Strous RD. Ethical considerations in clinical training, care and research in psychopharmacology. Int J Neuropsychopharmacol. 2011;14(3):413–424. doi:10.1017/S1461145710001112.
National Institute of Neurological Disorders and Stroke. Parkinson’s disease. Available from: https://www.ninds.nih.gov/health-information/disorders/parkinsons-disease
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Asha D. Thakor, Rakshit M Dharajiya, Misbah Z. Shaikh, Amar M. Raval
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
AUTHORS WHO PUBLISH WITH THIS JOURNAL AGREE TO THE FOLLOWING TERMS:
Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 4.0 Unported License. that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
. 